Want to see DCTH full AI Analyst Report?
DCTH Stock Chart & Stats
$10.86
-$0.29(-2.36%)
At close: 4:00 PM EST
$10.86
-$0.29(-2.36%)
Day’s Range― - ―
52-Week Range$8.12 - $13.74
Previous CloseN/A
Volume96.76K
Average Volume (3M)507.70K
Market Cap
$434.63M
Enterprise Value$245.88
Total Cash (Recent Filing)$89.30M
Total Debt (Recent Filing)$907.00K
Price to Earnings (P/E)786.9
Beta1.49
Next Earnings
Aug 10, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding34,521,650
10 Day Avg. Volume354,826
30 Day Avg. Volume507,697
Financial Highlights & Ratios
PEG Ratio3.81
Price to Book (P/B)3.25
Price to Sales (P/S)4.24
P/FCF Ratio17.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.67Price Target Upside108.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.56
Revenue Forecast (FY)$103.24M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Scale-upSustained multi-year revenue expansion indicates durable commercial adoption of the HEPZATO kit across treatment centers. This scale supports recurring kit sales, improves per-unit economics and strengthens the revenue base for reinvestment and clinical expansion over the next 2–6 months.
Consistent Cash Generation And Positive Free Cash FlowReliable OCF and FCF over trailing periods demonstrate the company converts revenues into cash, providing a durable funding source for commercial rollouts and R&D without immediate external financing. This improves financial flexibility and supports multi-quarter growth investments.
Conservative Balance Sheet With Low LeverageA low-debt balance sheet and materially improved equity provide a structural cushion against execution slippages and allow the company to fund operations, buybacks, and clinical programs. This reduces refinancing risk and preserves optionality over months ahead.
Bears Say
Thin, Volatile Operating ProfitabilityOperating income remains fragile and inconsistent: negative TTM EBIT despite small GAAP net profit signals earnings quality issues driven by non‑operating items or timing. Durable profitability improvement must arrive to sustain margins as commercial and SG&A/R&D scale.
Rising R&D And SG&A PressurePlanned large increases in R&D and SG&A reflect deliberate investment but will structurally compress adjusted EBITDA and require consistent revenue execution to offset. Elevated, sustained spending raises breakeven needs and increases sensitivity to adoption rates over the medium term.
Site Activation And Clinical Enrollment RiskSlower-than-expected site activations and lagging enrollment can delay revenue from new patient flows and postpone evidence generation for label/indication expansion. These operational bottlenecks are structural to the commercial rollout and can impair medium-term growth visibility.
Delcath Systems News
DCTH FAQ
What was Delcath Systems, Inc.’s price range in the past 12 months?
Delcath Systems, Inc. lowest stock price was $8.12 and its highest was $13.74 in the past 12 months.
What is Delcath Systems, Inc.’s market cap?
Delcath Systems, Inc.’s market cap is $434.63M.
When is Delcath Systems, Inc.’s upcoming earnings report date?
Delcath Systems, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 19 days.
How were Delcath Systems, Inc.’s earnings last quarter?
Delcath Systems, Inc. released its earnings results on May 07, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.097 by $0.067.
Is Delcath Systems, Inc. overvalued?
According to Wall Street analysts Delcath Systems, Inc.’s price is currently Undervalued.
Does Delcath Systems, Inc. pay dividends?
Delcath Systems, Inc. does not currently pay dividends.
What is Delcath Systems, Inc.’s EPS estimate?
Delcath Systems, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Delcath Systems, Inc. have?
Delcath Systems, Inc. has 34,521,650 shares outstanding.
What happened to Delcath Systems, Inc.’s price movement after its last earnings report?
Delcath Systems, Inc. reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.097. Following the earnings report the stock price went down -0.178%.
Which hedge fund is a major shareholder of Delcath Systems, Inc.?
Currently, no hedge funds are holding shares in DCTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Delcath Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.67 (108.72% Upside)
$22.67 (108.72% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 65.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
42.97%
Trailing 12-Months
Company Description
Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
DCTH Stock 12 Month Forecast
Average Price Target
$22.67
▲(108.72% Upside)
Technical Analysis
Ownership Overview
21.79% Insiders
7.31% Mutual Funds
1.10% Other Institutional Investors
61.21% Public Companies and
Individual Investors